Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from Georgetown University.
2436 articles by Ned Pagliarulo
-
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
Feb. 29, 2024 -
Janux shares triple on early cancer immunotherapy data
Feb. 27, 2024 -
Minerva schizophrenia drug rejected by FDA
Feb. 27, 2024 -
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
Feb. 23, 2024 -
Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’
Feb. 22, 2024 -
AstraZeneca gets new Tagrisso OK as drug succeeds in another trial
Feb. 20, 2024 -
Ipsen drug approved by FDA for early pancreatic cancer
Feb. 14, 2024 -
Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex
Feb. 14, 2024 -
Gilead to buy CymaBay in $4.3B deal for liver disease drug
Feb. 12, 2024 -
Obesity drug mania takes over Amgen’s earnings call
Feb. 7, 2024 -
Merck keeps deal focus with Keytruda patent cliff on horizon
Feb. 1, 2024 -
New CMS pilot to test payment scheme for pricey sickle cell gene therapies
Jan. 31, 2024 -
Regeneron to acquire 2seventy’s cell therapy pipeline
Jan. 30, 2024 -
Non-opioid drug from Vertex cuts pain in major trial tests
Jan. 30, 2024 -
Sarepta data show new Duchenne drug’s potency, but highlight side effects
Jan. 29, 2024 -
RayzeBio drew other pharma interest before Bristol Myers deal
Jan. 25, 2024 -
Lilly gene therapy finding puts focus on hearing loss treatment pipeline
Jan. 24, 2024 -
Sanofi to buy Inhibrx in deal worth up to $2.2B
Jan. 23, 2024 -
Novartis details first-line data for radiopharma drug Lutathera
Jan. 19, 2024 -
Gene therapy biotech Jaguar spins out manufacturing company
Jan. 18, 2024 -
BridgeBio strikes drug royalty deal for cash infusion
Jan. 18, 2024 -
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia
Jan. 16, 2024 -
The biopharma industry outlook on 2024: Guarded optimism for a rebound
Jan. 16, 2024 -
Backed by billionaires, a new biomedical institute tests an unorthodox approach
Jan. 12, 2024 -
5 questions facing pharma in 2024
Jan. 10, 2024